Ding GQ, Qin MF, Zou FS, Zhao HZ. Oral magnesium prevents the development of pancreatitis and hyperamylasemia in patients after ERCP.
Shijie Huaren Xiaohua Zazhi 2012;
20:1570-1573. [DOI:
10.11569/wcjd.v20.i17.1570]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the effect of oral magnesium on the development of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) and hyperamylasemia.
METHODS: One hundred and twenty patients with cholelithiasis were randomly divided into two groups: magnesium group (n = 60), in which 50% magnesium was given 30 min before ERCP, and control group (n = 60), in which no magnesium was given. Serum levels of amylase were measured in all the patients before ERCP and at 3 and 24 h after ERCP. The incidences of hyperamylasemia and PEP were also observed.
RESULTS: Serum levels of amylase did not differ significantly before ERCP between the two groups (P > 0.05), but were higher in both groups at 3 and 24 h after ERCP than before ERCP, and were lower in the magnesium group than in the control group at 3 and 24 h after ERCP. The incidences of hyperamylasemia and PEP in magnesium group were significantly lower than those in the control group (both P < 0.05).
CONCLUSION: Oral magnesium may decrease serum levels of amylase and prevent the occurrence of PEP and hyperamylasemia in patients after ERCP.
Collapse